BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Table 4 Grade ≥ 3 treatment-related adverse events in the two groups, n (%)
Grade ≥ 3 AEs
Control group (n = 92)
Experimental group (n = 31)
P value
Myelosuppression3 (3.26)3 (9.68)0.341
Nausea3 (3.26)0 (0.00)0.730
Diarrhea3 (3.26)0 (0.00)0.730
Fatigue1 (1.09)1 (3.23)1.000
Proteinuria2 (2.17)0 (0.00)0.995
Hypertension2 (2.17)0 (0.00)0.995
Hepatic dysfunction3 (3.26)1 (3.23)1.000
Thyroid dysfunction0 (0.00)1 (3.23)0.566
Hand-foot syndrome0 (0.00)0 (0.00)1.000


Write to the Help Desk